摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Amoxicillin and clavulanic acid | 79198-29-1

中文名称
——
中文别名
——
英文名称
Amoxicillin and clavulanic acid
英文别名
(2S,5R,6R)-6-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2R,3Z,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
Amoxicillin and clavulanic acid化学式
CAS
79198-29-1
化学式
C24H28N4O10S
mdl
——
分子量
564.6
InChiKey
QJVHTELASVOWBE-AGNWQMPPSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -1.07
  • 重原子数:
    39
  • 可旋转键数:
    6
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.46
  • 拓扑面积:
    245
  • 氢给体数:
    6
  • 氢受体数:
    12

ADMET

毒理性
  • 在妊娠和哺乳期间的影响
哺乳期使用总结:有限的信息表明,在哺乳期使用阿莫西林-克拉维酸期间,婴儿出现不良反应是不常见的,偶尔会出现不安、腹泻和皮疹。阿莫西林-克拉维酸在哺乳期母亲中是可以接受的。 对哺乳婴儿的影响:一项小型的、控制的、前瞻性研究让母亲监测她们的婴儿是否有不良反应的迹象(舌头起毛、喂养困难、大便频率和稠度的变化、尿布疹和皮肤疹)。还记录了体重变化和黄疸的发展。在这些参数上,对照组母亲的婴儿和服用阿莫西林-克拉维酸的14位母亲的婴儿之间没有发现统计学的差异。[2] 一项前瞻性、控制性研究询问了打电话咨询信息服务关于她们哺乳婴儿出现不良反应的母亲。母亲们正在服用阿莫西林或阿莫西林-克拉维酸。总体来说,在阿莫西林-克拉维酸组(22.3%)的婴儿中不良反应的发生率在统计学上高于阿莫西林组(7.5%),并且不良反应的几率与剂量有关。阿莫西林-克拉维酸的反应包括不安(8.9%)、腹泻(5.9%)、皮疹(5.9%)和便秘(1.5%),尽管没有单个不良反应在统计学上比阿莫西林组更常见。一名婴儿的母亲每天服用1.5克阿莫西林-克拉维酸,在母亲治疗期间婴儿的肝酶(AST和ALT)轻度升高,停药后10天恢复正常。[3] 一名从出生就开始哺乳的2个月大婴儿。他的母亲在怀孕期间服用了很多药物,但她不记得它们的身份。她患上了乳腺炎,并用阿莫西林-克拉维酸1克口服,每12小时一次,庆大霉素160毫克肌肉注射,每天一次。婴儿在两种药物的首剂后15分钟开始哺乳了10分钟。大约20分钟后,婴儿出现了全身性荨麻疹,30分钟后消失。几个小时后,婴儿再次哺乳,15分钟后荨麻疹再次出现,1小时后消失。在改用配方奶并且不再接触青霉素后,随访到16个月大时,反应没有再出现。不良反应很可能是由于母乳中的抗生素引起的。导致反应的药物无法确定,但很可能是阿莫西林-克拉维酸。[4] 对哺乳和母乳的影响:截至修订日期,没有找到相关的已发布信息。
◉ Summary of Use during Lactation:Limited information indicates that adverse reactions in infants are uncommon during the use of amoxicillin-clavulanic acid during nursing, with restlessness, diarrhea and rash occurring occasionally. Amoxicillin-clavulanic acid is acceptable in nursing mothers. ◉ Effects in Breastfed Infants:A small, controlled, prospective study had mothers monitor their infants for signs of adverse effects (furring of the tongue, feeding difficulties, changes in stool frequency and consistency, diaper rash, and skin rash). Weight change and the development of jaundice were also recorded. No statistical differences in these parameters were found between the infants of the control mothers and those of the 14 mothers taking amoxicillin-clavulanate.[2] A prospective, controlled study asked mothers who called an information service about adverse reactions experience by their breastfed infants. Mothers were taking either amoxicillin or amoxicillin-clavulanic acid. Overall, adverse reactions in the infants were statistically more frequent in the amoxicillin-clavulanic acid group (22.3%) than in the amoxicillin group (7.5%) and the rate of adverse effects was dose-related. Amoxicillin-clavulanate reactions consisted of restlessness (8.9%), diarrhea (5.9%), rash (5.9%), and constipation (1.5%), although no single adverse effect was statistically more frequent than in the amoxicillin group. One infant whose mother was taking 1.5 g daily of amoxicillin-clavulanic acid developed mildly elevated liver enzymes (AST and ALT) during maternal therapy that returned to normal 10 days after discontinuation of the drug.[3] A 2-month-old infant breastfed since birth. His mother had taken many medications during pregnancy, but she did not recall their identity. She developed mastitis and was treated with amoxicillin-clavulanic acid 1 gram orally every 12 hours and gentamicin 160 mg intramuscularly once daily. The infant was breastfed for 10 minutes starting 15 minutes after the first dose of both drugs. About 20 minutes later, the infant developed a generalized urticaria which disappeared after 30 minutes. A few hours later, the infant breastfed again and the urticaria reappeared after 15 minutes and disappeared after an hour. After switching to formula feeding and no further infant exposure to penicillins, the reaction did not reappear with follow-up to 16 months of age. The adverse reaction was probably caused by the antibiotics in breastmilk. The drug that caused the reaction cannot be determined, but it was most likely the amoxicillin-clavulanic acid.[4] ◉ Effects on Lactation and Breastmilk:Relevant published information was not found as of the revision date.
来源:Drugs and Lactation Database (LactMed)
毒理性
  • 在妊娠和哺乳期间的影响
◈ 什么是阿莫西林和克拉维酸? 这两种药物联合使用制成一种抗生素,用于治疗细菌感染。阿莫西林是一种类似青霉素的抗生素,克拉维酸是一种增强阿莫西林效果的药物。一些品牌名称包括Amoclav®、Augmentin XR®和Clavamox®。有时当人们发现怀孕时,他们会考虑改变用药方式,或者完全停止用药。然而,在做出任何改变之前,与您的医疗保健提供者交谈非常重要。您的医疗保健提供者可以与您讨论治疗您病情的好处以及怀孕期间未治疗疾病的风险。 ◈ 我服用阿莫西林和克拉维酸。这会使我更难怀孕吗? 尚未进行过研究,以了解服用阿莫西林和克拉维酸是否会使怀孕变得更加困难。 ◈ 服用阿莫西林和克拉维酸会增加流产的风险吗? 任何怀孕都可能出现流产。尚未进行过研究,以观察阿莫西林和克拉维酸是否会增加流产的风险。 ◈ 服用阿莫西林和克拉维酸会增加出生缺陷的风险吗? 每例怀孕一开始就有3-5%的出生缺陷风险。这被称为背景风险。大多数研究没有发现,如果在怀孕第一季度服用阿莫西林和克拉维酸,会增加出生缺陷的风险;然而,可用研究非常少。有更多的研究观察了怀孕期间单独使用阿莫西林的情况。有几项研究发现,如果在怀孕第一季度服用阿莫西林,会增加唇裂(唇部形成不正确)和/或腭裂(口腔顶部开口)的风险。然而,也有其他研究没有发现唇裂和/或腭裂的风险增加。根据目前的信息,如果一个人在怀孕期间服用阿莫西林和克拉维酸,唇裂和/或腭裂的总体风险被认为是低的。 ◈ 怀孕期间服用阿莫西林和克拉维酸会增加其他与怀孕相关问题的风险吗? 关于在怀孕第二季度使用阿莫西林和克拉维酸的信息有限,但迄今为止的研究并未报告在此时使用会增加怀孕问题(如早产[出生在37周之前]或低出生体重[出生时体重低于5磅8盎司(2500克)])的风险。对于第三季度的使用,有一项大型研究发现,使用阿莫西林和克拉维酸会增加早产的风险,这是一种在37周之前开始分娩的情况。接受阿莫西林和克拉维酸治疗的人被发现其新生儿患有一种严重的细菌感染,称为坏死性小肠结肠炎(NEC)的几率略有增加。这是一种可能伤害婴儿肠道的状况。进一步审查发现,有些研究证实了这种风险,而其他研究则没有。总的来说,阿莫西林和克拉维酸的使用增加NEC风险的可能性被认为是低的。 ◈ 怀孕期间服用阿莫西林和克拉维酸会影响孩子的未来行为或学习吗? 一项跟踪数百名儿童至11岁的研究发现,产前暴露于阿莫西林和克拉维酸并未与学习或行为问题相关。 ◈ 服用阿莫西林和克拉维酸时哺乳: 阿莫西林和克拉维酸会进入母乳,但根据少量研究,并未显示这会大大增加对哺乳婴儿的副作用风险。一项对67名哺乳婴儿的研究没有发现严重副作用的高风险。尽管有些婴儿出现了皮疹、腹泻、烦躁和便秘等副作用,但这些反应并未持续很久。早产儿或年龄小于一个月的婴儿的胃和肠道比大婴儿不太成熟,这可能使更多的药物进入他们的血液。如果您认为您的宝宝可能因为您奶中的药物而出现副作用,请与您孩子的医疗保健提供者交谈。务必与您的医疗保健提供者讨论所有关于哺乳的问题。 ◈ 如果男性服用阿莫西林和克拉维酸,会影响生育能力(使伴侣怀孕的能力)或增加出生缺陷的风险吗? 尚未进行过研究,以了解阿莫西林和克拉维酸是否会影响男性生育能力或增加出生缺陷的风险。一般来说,父亲或精子捐献者的暴露不太可能增加怀孕的风险。更多信息,请参阅MotherToBaby事实表《父亲暴露与怀孕》https://mothertobaby.org/fact-sheets/paternal-exposures-pregnancy/。
◈ What is amoxicillin and clavulanic acid? These 2 medications are combined to make an antibiotic that is used to treat bacterial infections. Amoxicillin is a penicillin-like antibiotic and clavulanic acid is a drug that increases the effectiveness of amoxicillin. Some brand names include Amoclav®, Augmentin XR® and Clavamox®.Sometimes when people find out they are pregnant, they think about changing how they take their medication, or stopping their medication altogether. However, it is important to talk with your healthcare providers before making any changes to how you take this medication. Your healthcare providers can talk with you about the benefits of treating your condition and the risks of untreated illness during pregnancy. ◈ I take amoxicillin and clavulanic acid. Can it make it harder for me to get pregnant? Studies have not been done to know if taking amoxicillin and clavulanic acid can make it harder to get pregnant. ◈ Does taking amoxicillin and clavulanic acid increase the chance for miscarriage? Miscarriage can occur in any pregnancy. Studies have not been done to see if amoxicillin and clavulanic acid increases the chance for miscarriage. ◈ Does taking amoxicillin and clavulanic acid increase the chance of birth defects? Every pregnancy starts out with a 3-5% chance of having a birth defect. This is called the background risk.Most studies have not found an increased chance for birth defects when amoxicillin and clavulanic acid is taken during the first trimester; however, there are very few studies available. There are more studies looking at the use of amoxicillin alone during pregnancy. A few studies have shown a higher chance of cleft lip (lip doesn’t form correctly) with or without cleft palate (opening in the roof of the mouth) when amoxicillin is taken during the first trimester. However, there are other studies that have not found a higher chance for cleft lip with or without cleft palate. Based on the current information, the overall chance of a cleft in lip and/or palate is considered to be low if a person is taking amoxicillin and clavulanic acid in a pregnancy. ◈ Does taking amoxicillin and clavulanic acid in pregnancy increase the chance of other pregnancy related problems? There is limited information regarding the use of amoxicillin and clavulanic acid during the second trimester, but studies so far do not report an increased chance for pregnancy problems such as preterm delivery (birth before week 37) or low birth weight (weighing less than 5 pounds, 8 ounces [2500 grams] at birth) when used in this time period.For use in the third trimester, there is one large study that found an increased chance for preterm labor, a condition in which the early stages of childbirth start before 37 weeks of pregnancy. The people treated with amoxicillin and clavulanic acid were found to have a small increased chance for a serious bacterial infection known as necrotizing enterocolitis (NEC) in their newborns. This is a condition that can injure a baby’s intestines. Further review has found some studies that confirm this chance and others that do not. Overall, the chance that the use of amoxicillin and clavulanic acid increases the risk of NEC is likely to be low. ◈ Does taking amoxicillin and clavulanic acid in pregnancy affect future behavior or learning for the child? One study that has followed hundreds of children up to age 11 years did not find that prenatal exposure to amoxicillin and clavulanic acid was linked to learning or behavior problems. ◈ Breastfeeding while taking amoxicillin and clavulanic acid: Amoxicillin and clavulanic acid enter the breast milk, however, based on a small number of studies; it has not been shown to greatly increase the chance side effects for a nursing baby. A study of 67 infants who were breastfeeding did not find a high chance of serious side effects. While some babies had side effects such as rash, diarrhea, irritability and constipation, the reactions did not last long. Infants that are born preterm or are younger than one month of age have a stomach and intestine that are less mature than older babies. This might allow more medication to enter their blood stream. If you think your baby has developed a side effect from medication that might be in your milk, talk to your child’s healthcare provider. Be sure to talk to your healthcare provider about all of your breastfeeding questions. ◈ If a male takes amoxicillin and clavulanic acid, could it affect fertility (ability to get partner pregnant) or increase the chance of birth defects? Studies have not been done to see if amoxicillin and clavulanic acid could affect male fertility or increase the chance of birth defects. In general, exposures that fathers or sperm donors have are unlikely to increase the risks to a pregnancy. For more information, please see the MotherToBaby fact sheet Paternal Exposures at https://mothertobaby.org/fact-sheets/paternal-exposures-pregnancy/.
来源:Mother To Baby Fact Sheets

文献信息

  • Maxillofacial bone augmentation using RHPDGF-BB and a biocompatible matrix
    申请人:Biomimetic Therapeutics, Inc.
    公开号:EP2431060A2
    公开(公告)日:2012-03-21
    The present invention provides effective new methods and uses for compositions for maxillofacial bone augmentation, particularly alveolar ridge augmentation, that are free of problems associated with prior art methods. In one embodiment, these materials include human recombinant platelet derived growth factor (rhPDGF-BB) and a biocompatible matrix. In another embodiment, these materials include rhPDGF-BB, a deproteinized bone block or calcium phosphate, and a bioresorbable membrane. The use of these materials in the present method is effective in regenerating maxillofacial bones and facilitating achievement of stable osseointegrated implants. The mandible and maxilla are preferred bones for augmentation, and enhancement of the alveolar ridge is a preferred embodiment of the present invention.
    本发明为颌面骨增量,特别是牙槽脊增量的组合物提供了有效的新方法和新用途,这些组合物不存在与现有技术方法相关的问题。在一个实施方案中,这些材料包括人重组血小板衍生生长因子(rhPDGF-BB)和生物相容性基质。在另一个实施方案中,这些材料包括 rhPDGF-BB、去蛋白骨块或磷酸钙以及生物可吸收膜。在本方法中使用这些材料可以有效地再生颌面部骨骼,并促进实现稳定的骨结合植入物。下颌骨和上颌骨是首选的增量骨骼,牙槽嵴的增量是本发明的优选实施方案。
  • Selectable needle syringe with retraction plunger
    申请人:UNL Holdings LLC
    公开号:US10195363B2
    公开(公告)日:2019-02-05
    The present embodiments provide for a syringe and a retraction plunger assembly configured to accept various retractable needle assemblies, which are capable of cooperating to provide a retraction safety syringe. In particular, the syringe includes a barrel and a retraction plunger assembly comprising a control unit attached to a plunger and releasably engaged to a housing, and at least one biasing means disposed within the plunger assembly. Upon completion of dose delivery via a retractable needle, the control unit disengages from housing and the biasing member retracts the plunger and a connected needle into the barrel. Various elements are configured to prevent further use of the syringe. The control unit can be used to control a rate of needle retraction.
    本实施例提供了一种注射器和缩回柱塞组件,其配置可接受各种可缩回针头组件,它们能够配合提供一种缩回安全注射器。特别是,注射器包括一个针筒和一个缩回柱塞组件,该组件包括一个连接到柱塞并可释放地啮合到外壳的控制单元,以及至少一个设置在柱塞组件内的偏压装置。通过可伸缩针头完成剂量输送后,控制单元脱离外壳,偏压装置将柱塞和连接的针头缩回枪管。各种元件的配置可防止进一步使用注射器。控制装置可用于控制针头缩回的速度。
  • Luer connection adapters for retractable needle syringes
    申请人:UNITRACT SYRINGE PTY LTD
    公开号:US10357621B2
    公开(公告)日:2019-07-23
    A connector mountable to a syringe barrel has a proximal barrel-engaging portion, a distal luer fitment portion, and a fluid aperture therethrough. The barrel-engaging portion of the connector includes an axial ledge configured to abut the axial distal edge of a glass syringe barrel. The connector facilitates mounting a luer assembly to the barrel. The luer assembly may be a tip cap having a complementary luer fitment for connection to the luer fitment portion of the connector. The luer assembly may be a luer needle assembly having a complementary luer fitment for connection to the luer fitment portion of the connector. The connector and syringe may further include an immobile, compressible needle seal. The needle seal is adjacent to or engageable with the barrel-engaging portion of the connector. The syringe may be configured with a plunger capable of engaging a retractable needle.
    一种可安装到注射器枪管上的连接器具有一个近端枪管啮合部分、一个远端鲁尔配合部分和一个流体孔。连接器的针筒啮合部分包括一个轴向凸缘,用于与玻璃注射器针筒的轴向远端边缘相接。连接器便于将鲁尔组件安装到针筒上。鲁尔接头组件可以是具有互补鲁尔接头的针尖帽,用于与连接器的鲁尔接头部分连接。鲁尔接头组件可以是鲁尔针组件,具有用于与连接器鲁尔接头部分连接的互补鲁尔接头。连接器和注射器可进一步包括一个不动的、可压缩的针头密封件。针头密封件与连接器的枪管啮合部分相邻或可啮合。注射器可配置一个能够与可伸缩针头啮合的柱塞。
  • Systems, apparatus, and methods for generating and analyzing resistome profiles
    申请人:OpGen, Inc.
    公开号:US10475526B2
    公开(公告)日:2019-11-12
    Systems, apparatus, and methods are disclosed for generating a resistome profile for a subject, monitoring an infection state of one or more subjects, and/or identifying a potential infection outbreak at a facility, for example, by obtaining first data representative of at least one measure of antibiotic resistance of an organism from a first sample, identifying the organism, determining at least one of an antibiotic susceptibility phenotype, an identity of an antibiotic resistance gene, and an antibiotic to which the organism is non-susceptible, generating and comparing a first pattern to at least one known pattern to determine and generate a profile uniqueness identifier indicating a degree of similarity above a threshold between the first pattern and the at least one known pattern.
    本发明公开了用于生成受试者抗性组图谱、监测一个或多个受试者的感染状态和/或识别设施中潜在感染爆发的系统、装置和方法,例如,通过从第一样本中获取代表生物体抗生素耐药性至少一种测量指标的第一数据,识别生物体、确定抗生素易感性表型、抗生素耐药基因的身份和该生物体不易感性的抗生素中的至少一种,生成第一模式并将其与至少一种已知模式进行比较,以确定并生成表明第一模式与至少一种已知模式之间的相似程度高于阈值的特征唯一性标识符。
  • Vaccine composition against Chlamydiaceae infections
    申请人:CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    公开号:US10695416B2
    公开(公告)日:2020-06-30
    The invention relates to vaccine compositions for treating and/or preventing infections by a bacterium of the Chlalmydiaceae family, said compositions comprising bacteria of the Chlamydiaceae family, which have been previously treated by at least one peptidoglycan inhibitor, or extracts of said treated bacteria.
    本发明涉及用于治疗和/或预防由衣壳菌科细菌引起的感染的疫苗组合物,所述组合物包括先前已用至少一种肽聚糖抑制剂处理过的衣壳菌科细菌,或所述处理过的细菌的提取物。
查看更多

同类化合物

(6R,7R)-7-苯基乙酰胺基-3-[(Z)-2-(4-甲基噻唑-5-基)乙烯基]-3-头孢唑啉-4-羧酸二苯甲基酯 顺式-4-(2,2-二甲氧基乙基)-3-邻苯二甲酰-2-氮杂环丁酮 顺式-1-(对甲苯基)-3-苄氧基-4-(对茴香基)-氮杂环丁烷-2-酮 青霉酰聚赖氨酸 青霉素钾 青霉素钠 青霉素酶液体 青霉素杂质C 青霉素G衍生物 青霉素G甲酯 青霉素G甲酯 青霉素G-D7 青霉素 V 钠 阿那白滞素 阿莫西林钠 阿莫西林三水合物 阿莫西林 阿立必利D5 阿度西林 铜(2+)酞菁-29,30-二负离子-2-(二甲氨基)乙醇(1:1:1) 钾(2S,5R,6R)-6-[[2-[(E)-3-氯丁-2-烯基]巯基乙酰基]氨基]-3,3-二甲基-7-氧代-4-硫杂-1-氮杂双环[3.2.0]庚烷-2-羧酸酯 钠(6S,7R)-3-(羟基甲基)-7-甲氧基-8-氧代-7-[(2-噻吩基乙酰基)氨基]-5-硫杂-1-氮杂双环[4.2.0]辛-2-烯-2-羧酸酯 酞氨西林 萘夫西林杂质 苯磺酸,2-[(2-羟基-1-萘基)偶氮]-5-甲基-,盐(2:1)钡 苯氧乙基青霉素钾 苯唑西林钠 苯唑西林杂质1 舒巴坦杂质19 舒他西林 脱乙酰基戊二酰 7-氨基头孢烷酸 脱乙酰基头孢噻肟 肟莫南 羰苄西林苯酯钠 美罗培南钠盐 美罗培南 美洛培南 缩酮氨苄青霉素 紫杉醇侧链2 硫霉素 硫霉素 硫酸氢3-{[(6R,7R)-7-{[(2E)-2-(2-氨基-1,3-噻唑-4-基)-2-(甲氧基亚氨基)乙酰基]氨基}-2-羧基-8-羰基-5-硫杂-1-氮杂二环[4.2.0]辛-2-烯-3-基]甲基}-1,3-噻唑-3-正离子 硫酸头孢噻利 硫酸头孢喹诺 盐酸巴氨西林 盐酸头孢唑兰 盐酸头孢吡肟 盐酸头孢他美酯 盐酸头孢他美 癸二酸与六氢-2H-氮杂卓-2-酮,1,6-己烷二胺和己二酸的聚合物